Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Pharmacology

• Publication date

  2015-08-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejphar.2015.06.015PMID 26073023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.

  2014cited by this paper
• Is there a new dawn for selective mineralocorticoid receptor antagonism?

  2014cited by this paper
• Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.

  2014cited by this paper
• [Revisiting the therapeutic concept of a mineralocorticoid receptor antagonist - focusing on resistant hypertension and chronic renal failure].

  2012cited by this paper
• SM-368229, a Novel Promising Mineralocorticoid Receptor Antagonist, Shows Antihypertensive Efficacy With Minimal Effect on Serum Potassium Level in Rats

  2012cited by this paper
• Discovery of BAY 94‐8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

  2012cited by this paper
• Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.

  2012cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.

  2011cited by this paper
• Aldosterone and inflammation

  2010cited by this paper
• Cardiovascular outcomes in patients with primary aldosteronism after treatment.

  2008cited by this paper
• Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation

  2008cited by this paper
• Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.

  2008cited by this paper
• Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker

  2008cited by this paper
• Podocyte as the Target for Aldosterone: Roles of Oxidative Stress and Sgk1

  2007cited by this paper
• Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

  2006cited by this paper
• Eplerenone: a selective aldosterone receptor antagonist (SARA).

  2006cited by this paper
• Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

  2005cited by this paper
• Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis

  2005cited by this paper
• Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

  2005cited by this paper
• Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability

  2005cited by this paper
• The Mineralocorticoid Receptor and Oxidative Stress

  2005cited by this paper
• The evolution of aldosterone antagonists.

  2004cited by this paper
• Efficacy and Safety of the Selective Aldosterone Blocker Eplerenone in Japanese Patients With Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Study

  2004cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats

  2003cited by this paper
• EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION

  2003cited by this paper
• Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans.

  2003cited by this paper
• Mineralocorticoid effects in the kidney: correlation between alphaENaC, GILZ, and Sgk-1 mRNA expression and urinary excretion of Na+ and K+.

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.

  2002cited by this paper
• The role of spironolactone in the treatment of patients with refractory hypertension.

  2001cited by this paper
• Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus.

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action.

  1998cited by this paper
• Water‐soluble β‐Cyclodextrins in Paediatric Oral Solutions of Spironolactone: Preclinical Evaluation of Spironolactone Bioavailability from Solutions of β‐Cyclodextrin Derivatives in Rats

  1998cited by this paper
• Aldosterone biosynthesis and action in vascular cells.

  1995cited by this paper
• Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart.

  1995cited by this paper
• Antialdosterones: incidence and prevention of sexual side effects.

  1989cited by this paper
• Efficacy and tolerance of spironolactone in essential hypertension.

  1987cited by this paper
• Renal target sites and the mechanism of action of aldosterone.

  1983cited by this paper
• Pathophysiology of spironolactone-induced gynecomastia.

  1977cited by this paper
• [Sexual side-effects of spironolactones. Possible mechanisms of their anti-androgen action].

  1976cited by this paper

• Esaxerenone Attenuates Cardiac Hypertrophy in a Pressure Overload Model in Mice.

  2025cites this paper
• Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study

  2025cites this paper
• Effect of N-terminal pro B-type natriuretic peptide levels on the efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of Japanese patients with uncontrolled essential hypertension: a subanalysis of the EXCITE-HT study

  2025cites this paper
• Esaxerenone Attenuates High Salt-Induced Hypertension and Renal Damage via CD8+T Cell- Associated NCC Activation in Aldosterone Treated Rats.

  2025cites this paper
• Esaxerenone Attenuates Atherogenesis and Vascular Dysfunction in Apolipoprotein E-Deficient Mice.

  2025cites this paper
• Efficacy and safety of esaxerenone with and without sodium–glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies

  2025cites this paper
• Short-term longitudinal clinical, biochemical, and quality of life outcomes of medical or surgical therapy in unilateral primary aldosteronism

  2025cites this paper
• Aldosterone in Chronic Kidney Disease

  2025cites this paper
• Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety

  2025cites this paper
• Safety of esaxerenone (CS-3150) and its impacts on blood pressure and renal function: A systematic review and meta-analysis

  2025influential citation
• Rationale and Design of the ESPIAL Trial　― A Prospective, Randomized, Exploratory Study to Evaluate the Effect of Esaxerenone on Reduction of Urinary Albumin to Creatinine Ratio in Hypertensive Patients Concomitant With Heart Failure and Albuminuria ―

  2025cites this paper
• Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies

  2025cites this paper
• Chronic esaxerenone treatment improves vascular function and lowers peripheral arterial stiffness in patients with idiopathic hyperaldosteronism

  2025cites this paper
• A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension

  2025cites this paper
• Esaxerenone Improves Vascular Endothelial Dysfunction by Reducing Serum and Glucocorticoid-Regulated Kinase 1 Activity and Enhancing the Akt Pathway in Type 2 Diabetic Mice.

  2025cites this paper
• Home blood pressure-lowering effect of esaxerenone vs trichlormethiazide for uncontrolled hypertension: a prespecified subanalysis of the EXCITE-HT randomized controlled study by age subgroup

  2025cites this paper
• Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors

  2025cites this paper
• Mechanisms of ligand-mediated modulation of mineralocorticoid receptor signaling.

  2025cites this paper
• Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists

  2024cites this paper
• Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)

  2024cites this paper
• Effect of esaxerenone on the onset of aortic endothelial dysfunction and circulating microparticles in type 1 diabetic male mice

  2024cites this paper
• Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity

  2024cites this paper
• Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker

  2024cites this paper
• Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex

  2024cites this paper
• Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models

  2024cites this paper
• Factors influencing the efficacy and safety of esaxerenone in hypertensive patients: a pooled analysis of five clinical studies on different comorbidities

  2024cites this paper
• Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study

  2024cites this paper
• Esaxerenone: blood pressure reduction and cardiorenal protection without reflex sympathetic activation in salt-loaded stroke-prone spontaneously hypertensive rats

  2024cites this paper
• Improvement in proteinuria with sodium-glucose cotransporter 2 inhibitors and esaxerenone treatment in patients with chronic allograft kidney disease: A case report

  2024cites this paper
• Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis

  2024cites this paper
• Novel 1,4-Dihydropyridine Derivatives as Mineralocorticoid Receptor Antagonists

  2023cites this paper
• Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease

  2023cites this paper
• Effect of esaxerenone on ischemia and reperfusion injury in rat hearts.

  2023cites this paper
• Structure-function relationships of the aldosterone receptor.

  2023cites this paper
• Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes

  2023influential citation
• Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.

  2023cites this paper
• Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks

  2023cites this paper
• Molecular pharmacology of mineralocorticoid receptor antagonists: the role of co-regulators.

  2023cites this paper
• ALDOSTERONE Mineralocorticoid Receptor (MR)-associated Hypertension: Over-activation of MR by 'Greedy Kidney and Guts' for salt and sugar

  2023cites this paper
• Biomarkers to Guide Medical Therapy in Primary Aldosteronism.

  2023cites this paper
• Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers.

  2023cites this paper
• The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction

  2023cites this paper
• New Allosteric Modulators of AMPA Receptors: Synthesis and Study of Their Functional Activity by Radioligand-Receptor Binding Analysis

  2023cites this paper
• Future treatments in hypertension: Can we meet the unmet needs of patients?

  2023cites this paper
• Recent progress in the diagnosis and treatment of primary aldosteronism

  2023cites this paper
• Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease

  2023cites this paper
• Aldosterone: Renal Action and Physiological Effects.

  2023cites this paper
• Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease

  2022cites this paper
• Themed Issue: Emerging Fields for Therapeutic Targeting of the Aldosterone-Mineralocorticoid Receptor Signaling Pathway

  2022influential citation
• Themed Issue: Emerging Fields for Therapeutic Targeting of the Aldosterone-Mineralocorticoid Receptor Signaling Pathway

  2022cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review

  2022cites this paper
• Bioequivalence of Esaxerenone Conventional Tablet and Orally Disintegrating Tablet: Two Single‐Dose Crossover Studies in Healthy Japanese Men

  2022cites this paper
• Aldosterone and cardiovascular diseases.

  2022cites this paper
• The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers

  2022cites this paper
• Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.

  2022cites this paper
• Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

  2022cites this paper
• A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice

  2022cites this paper
• Esaxerenone Blocks Vascular Endothelial Inflammation Through SGK1

  2022cites this paper
• Esaxerenone, a selective mineralocorticoid receptor blocker, improves insulin sensitivity in mice consuming high-fat diet.

  2022cites this paper
• Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats

  2022cites this paper
• Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect

  2022cites this paper
• Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.

  2022cites this paper
• Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone

  2022cites this paper
• Novel therapies on the horizon of hypertension management.

  2022cites this paper
• The role of blood pressure management in stroke prevention: current status and future prospects

  2022cites this paper
• Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus

  2022influential citation
• Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease

  2022cites this paper
• Effect of Nonsteroidal Mineralocorticoid Receptor Blocker Esaxerenone on Vasoreactivity to an Endothelial Stimulator in Superior Mesenteric Arteries of Type 2 Diabetic Goto-Kakizaki Rat.

  2022cites this paper
• Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents.

  2021cites this paper
• Efficacy of esaxerenone—a nonsteroidal mineralocorticoid receptor blocker—on nocturnal hypertension

  2021cites this paper
• Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials

  2021cites this paper
• Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

  2021cites this paper
• Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study

  2021cites this paper
• Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

  2021cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonism for cardiovascular and renal disorders - new perspectives for combination therapy.

  2021cites this paper
• Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes

  2021cites this paper
• Recent Advances in Catalytic Atroposelective Construction of Pentatomic Heterobiaryl Scaffolds

  2021cites this paper
• Topical Treatment of Human Skin and Cultured Keratinocytes with High-Dose Spironolactone Reduces XPB Expression and Induces Toxicity

  2021cites this paper
• Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone

  2021cites this paper
• Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease

  2021cites this paper
• Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists

  2021cites this paper
• Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats

  2021cites this paper
• Brain mineralocorticoid receptor in health and disease: From molecular signalling to cognitive and emotional function

  2021cites this paper
• Effects of mineralocorticoid receptor antagonists on sex hormones and body composition in patients with primary aldosteronism

  2021cites this paper
• Striatin heterozygous mice are more sensitive to aldosterone-induced injury

  2020cites this paper
• Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

  2020cites this paper
• Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)

  2020cites this paper
• Recent Research Advances in Renin-Angiotensin-Aldosterone System Receptors

  2020cites this paper
• Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction

  2020cites this paper
• Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone

  2020cites this paper
• Role of mineralocorticoid receptor antagonists in kidney diseases

  2020cites this paper
• Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study

  2020cites this paper
• Mineralocorticoid receptor antagonists in patients with chronic kidney disease.

  2020cites this paper
• Sodium butyrate ameliorates deoxycorticosterone acetate/salt-induced hypertension and renal damage by inhibiting the MR/SGK1 pathway

  2020cites this paper
• [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro® tablets 1.25 mg, 2.5 mg, 5 mg)].

  2020cites this paper
• A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity

  2020cites this paper
• Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease

  2020influential citation
• Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models

  2020cites this paper
• Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker

  2020cites this paper
• Recent advances in the management of secondary hypertension: chronic kidney disease

  2020cites this paper